Summer Sale
50% off Premium Yearly
Opinions David Burrows
Gilead Sciences Inc.GILDBUYMay 09, 2013
Stock price when the opinion was issued
As of Jun 18, 2026. Market Open.
You might be interested:
It's a biopharma which as a group did very well last year. Compare that to the smaller biotechs which have not done well the past 3 years. This year, biopharma and staples have underperformed. This boasts a high free cash flow yield and has a great product cycle coming.
In past years, biotech was the safe trade, but this year risk is back, so these stocks have fallen out of favour. Also, there are so many drugs in trials now and big pharma needs new product. She's looking at Gilead and Moderna, because they have low PEs and alot of drugs in development. However, the overall sector is risky.
Has long owned this, because it's a value stock and keeps raising its dividend.
Brian Belski
Jim Lebenthal
;fill-opacity:1;'/%3e%3cpath%20d='M31%2018.6001V30H8V18.6001L14.1334%2022.4334L19.4999%2014L24.8669%2022.4334L31%2018.6001Z'%20fill='%23EE5432'%20style='fill:%23EE5432;fill:color(display-p3%200.9340%200.3310%200.1956);fill-opacity:1;'/%3e%3c/svg%3e){kind=small}
Premium content
Premium content
It's bottoming because of interest rates. Sell it at $65. You can also swap this for Bristol-Myers.
Biotech group has been performing extremely well. There is growth and there is an expectation that they will be bought by a traditional drug company. You are buying something for growth here. Prefers to own the group, such as XBI-N, an ETF.